Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LONESTAR
NCT03391869Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2017
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03391869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391869.